# U.S. Gold Corp.: financial statements, quarterly

USAU · Nasdaq · CIK 27093 · [Materials](/sectors/materials.md) · fiscal year ends Apr 30

Pages: [Overview](/companies/usau.md) · [Financials](/companies/usau/financials.md) · [Filings](/companies/usau/filings.md) · [Insiders](/companies/usau/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/usau/financials.md?period=annual).

## Income statement

| Line item | Unit | Q2 FY2024 (2023-10-31) | Q3 FY2024 (2024-01-31) | Q4 FY2024 (2024-04-30) | Q1 FY2025 (2024-07-31) | Q2 FY2025 (2024-10-31) | Q3 FY2025 (2025-01-31) | Q4 FY2025 (2025-04-30) | Q1 FY2026 (2025-07-31) | Q2 FY2026 (2025-10-31) | Q3 FY2026 (2026-01-31) | Q4 FY2026 (2026-04-30) | Q1 FY2027 (2026-07-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Cost of revenue | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Research and development | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Selling, general and administrative | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating income | $k | [(1,765)](/filings/0001493152-24-050244.md) | [(1,275)](/filings/0001493152-25-010617.md) | [(1,287) d](/filings/0001641172-25-021368.md) | [(2,593)](/filings/0001493152-25-013494.md) | [(2,142)](/filings/0001493152-25-027102.md) | [(5,090)](/filings/0001493152-26-010290.md) | [(3,180) d](/filings/0001493152-26-035188.md) | [(3,638)](/filings/0001493152-26-042381.md) | [(4,555)](/filings/0001493152-25-027102.md) | [(5,347)](/filings/0001493152-26-010290.md) | [(5,460) d](/filings/0001493152-26-035188.md) | [(4,759)](/filings/0001493152-26-042381.md) |
| Income tax | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Net income | $k | [(258)](/filings/0001493152-25-010617.md) | [(1,686)](/filings/0001493152-25-010617.md) | [(2,059) d](/filings/0001641172-25-021368.md) | [(4,325)](/filings/0001493152-26-010290.md) | [(2,103)](/filings/0001493152-26-010290.md) | [(6,362)](/filings/0001493152-26-010290.md) | [(7,769) d](/filings/0001493152-26-035188.md) | [(2,077)](/filings/0001493152-26-042381.md) | [(4,483)](/filings/0001493152-26-010290.md) | [(5,284)](/filings/0001493152-26-010290.md) | [(5,364) d](/filings/0001493152-26-035188.md) | [(4,601)](/filings/0001493152-26-042381.md) |
| Diluted EPS | $ per share | [(0.03)](/filings/0001493152-24-050244.md) | [(0.18)](/filings/0001493152-25-010617.md) | not reported | [(0.40)](/filings/0001493152-25-013494.md) | [(0.20)](/filings/0001493152-25-027102.md) | [(0.54)](/filings/0001493152-26-010290.md) | not reported | [(0.15)](/filings/0001493152-26-042381.md) | [(0.31)](/filings/0001493152-25-027102.md) | [(0.35)](/filings/0001493152-26-010290.md) | not reported | [(0.28)](/filings/0001493152-26-042381.md) |
| Basic EPS | $ per share | [(0.03)](/filings/0001493152-24-050244.md) | [(0.18)](/filings/0001493152-25-010617.md) | not reported | [(0.40)](/filings/0001493152-25-013494.md) | [(0.20)](/filings/0001493152-25-027102.md) | [(0.54)](/filings/0001493152-26-010290.md) | not reported | [(0.15)](/filings/0001493152-26-042381.md) | [(0.31)](/filings/0001493152-25-027102.md) | [(0.35)](/filings/0001493152-26-010290.md) | not reported | [(0.28)](/filings/0001493152-26-042381.md) |

- Revenue: not reported
- Cost of revenue: not reported
- Research and development: not reported
- Selling, general and administrative: not reported
- Operating income: us-gaap:OperatingIncomeLoss
- Income tax: not reported
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q2 FY2024 (2023-10-31) | Q3 FY2024 (2024-01-31) | FY2024 (2024-04-30) | Q1 FY2025 (2024-07-31) | Q2 FY2025 (2024-10-31) | Q3 FY2025 (2025-01-31) | FY2025 (2025-04-30) | Q1 FY2026 (2025-07-31) | Q2 FY2026 (2025-10-31) | Q3 FY2026 (2026-01-31) | FY2026 (2026-04-30) | Q1 FY2027 (2026-07-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [4.0](/filings/0001493152-23-045000.md) | [2.6](/filings/0001493152-24-010294.md) | [5.6](/filings/0001641172-25-021368.md) | [3.4](/filings/0001493152-24-036365.md) | [1.6](/filings/0001493152-24-050244.md) | [9.1](/filings/0001493152-25-010617.md) | [8.2](/filings/0001493152-26-035188.md) | [11.3](/filings/0001493152-25-013494.md) | [8.8](/filings/0001493152-25-027102.md) | [36.1](/filings/0001493152-26-010290.md) | [30.7](/filings/0001493152-26-042381.md) | [27.1](/filings/0001493152-26-042381.md) |
| Current assets | $m | [4.5](/filings/0001493152-23-045000.md) | [3.0](/filings/0001493152-24-010294.md) | [6.5](/filings/0001641172-25-021368.md) | [4.1](/filings/0001493152-24-036365.md) | [2.2](/filings/0001493152-24-050244.md) | [10.0](/filings/0001493152-25-010617.md) | [8.9](/filings/0001493152-26-035188.md) | [12.3](/filings/0001493152-25-013494.md) | [9.8](/filings/0001493152-25-027102.md) | [36.8](/filings/0001493152-26-010290.md) | [32.2](/filings/0001493152-26-042381.md) | [28.5](/filings/0001493152-26-042381.md) |
| Total assets | $m | [20.2](/filings/0001493152-23-045000.md) | [18.9](/filings/0001493152-24-010294.md) | [22.6](/filings/0001641172-25-021368.md) | [20.1](/filings/0001493152-24-036365.md) | [18.2](/filings/0001493152-24-050244.md) | [26.0](/filings/0001493152-25-010617.md) | [24.9](/filings/0001493152-26-035188.md) | [28.3](/filings/0001493152-25-013494.md) | [27.1](/filings/0001493152-25-027102.md) | [54.8](/filings/0001493152-26-010290.md) | [50.2](/filings/0001493152-26-042381.md) | [46.5](/filings/0001493152-26-042381.md) |
| Current liabilities | $m | [0.5](/filings/0001493152-23-045000.md) | [0.3](/filings/0001493152-24-010294.md) | [0.5](/filings/0001641172-25-021368.md) | [0.6](/filings/0001493152-24-036365.md) | [0.5](/filings/0001493152-24-050244.md) | [0.8](/filings/0001493152-25-010617.md) | [0.9](/filings/0001493152-26-035188.md) | [1.0](/filings/0001493152-25-013494.md) | [1.7](/filings/0001493152-25-027102.md) | [1.4](/filings/0001493152-26-010290.md) | [0.6](/filings/0001493152-26-042381.md) | [0.8](/filings/0001493152-26-042381.md) |
| Total liabilities | $m | [4.0](/filings/0001493152-23-045000.md) | [4.2](/filings/0001493152-24-010294.md) | [5.1](/filings/0001641172-25-021368.md) | [7.0](/filings/0001493152-24-036365.md) | [6.9](/filings/0001493152-24-050244.md) | [8.5](/filings/0001493152-25-010617.md) | [13.3](/filings/0001493152-26-035188.md) | [1.8](/filings/0001493152-25-013494.md) | [2.5](/filings/0001493152-25-027102.md) | [2.2](/filings/0001493152-26-010290.md) | [1.5](/filings/0001493152-26-042381.md) | [1.6](/filings/0001493152-26-042381.md) |
| Short-term borrowings | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [16.3](/filings/0001493152-25-010617.md) | [14.7](/filings/0001493152-25-010617.md) | [17.5](/filings/0001493152-26-035188.md) | [13.2](/filings/0001493152-26-010290.md) | [11.2](/filings/0001493152-26-010290.md) | [17.5](/filings/0001493152-26-010290.md) | [11.6](/filings/0001493152-26-042381.md) | [26.5](/filings/0001493152-26-042381.md) | [24.6](/filings/0001493152-26-010290.md) | [52.6](/filings/0001493152-26-010290.md) | [48.8](/filings/0001493152-26-042381.md) | [44.9](/filings/0001493152-26-042381.md) |

- Cash and equivalents: us-gaap:Cash
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Short-term borrowings: not reported
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q2 FY2024 (2023-10-31) | Q3 FY2024 (2024-01-31) | Q4 FY2024 (2024-04-30) | Q1 FY2025 (2024-07-31) | Q2 FY2025 (2024-10-31) | Q3 FY2025 (2025-01-31) | Q4 FY2025 (2025-04-30) | Q1 FY2026 (2025-07-31) | Q2 FY2026 (2025-10-31) | Q3 FY2026 (2026-01-31) | Q4 FY2026 (2026-04-30) | Q1 FY2027 (2026-07-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [(2,051) d](/filings/0001493152-24-050244.md) | [(1,327) d](/filings/0001493152-25-010617.md) | [(1,890) d](/filings/0001641172-25-021368.md) | [(2,194)](/filings/0001493152-25-013494.md) | [(1,818) d](/filings/0001493152-25-027102.md) | [(3,141) d](/filings/0001493152-26-010290.md) | [(2,720) d](/filings/0001493152-26-035188.md) | [(3,315)](/filings/0001493152-26-042381.md) | [(3,795) d](/filings/0001493152-25-027102.md) | [(5,022) d](/filings/0001493152-26-010290.md) | [(6,081) d](/filings/0001493152-26-035188.md) | [(3,541)](/filings/0001493152-26-042381.md) |
| Capital expenditure | $k | not reported | not reported | not reported | not reported | not reported | not reported | [0.0 d](/filings/0001493152-26-035188.md) | not reported | not reported | [805 d](/filings/0001493152-26-010290.md) | [(1,921) d](/filings/0001493152-26-035188.md) | not reported |
| Share repurchases | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment, us-gaap:PaymentsToAcquireProductiveAssets
- Share repurchases: not reported

## Shares

| Line item | Unit | Q2 FY2023 (2022-10-31) | Q3 FY2023 (2023-01-31) | Q1 FY2024 (2023-07-31) | Q2 FY2024 (2023-10-31) | Q3 FY2024 (2024-01-31) | Q1 FY2025 (2024-07-31) | Q2 FY2025 (2024-10-31) | Q3 FY2025 (2025-01-31) | Q1 FY2026 (2025-07-31) | Q2 FY2026 (2025-10-31) | Q3 FY2026 (2026-01-31) | Q1 FY2027 (2026-07-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [8.3](/filings/0001493152-23-045000.md) | [8.4](/filings/0001493152-24-010294.md) | [9.3](/filings/0001493152-24-036365.md) | [9.3](/filings/0001493152-24-050244.md) | [9.3](/filings/0001493152-25-010617.md) | [10.7](/filings/0001493152-25-013494.md) | [10.7](/filings/0001493152-25-027102.md) | [11.8](/filings/0001493152-26-010290.md) | [13.9](/filings/0001493152-26-042381.md) | [14.3](/filings/0001493152-25-027102.md) | [15.3](/filings/0001493152-26-010290.md) | [16.5](/filings/0001493152-26-042381.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 16,528,663 at 2026-09-10, from the cover of the [10-Q filed 2026-09-11](/filings/0001493152-26-042381.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:18 ET. No prices; not investment advice.